about
Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects.Therapy of obstetrical infections with moxalactam.A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy.Antimicrobial susceptibilities of anaerobic bacteria isolated from female genital tract infections.Comparison of moxalactam and cefazolin as prophylactic antibiotics during cesarean section.Moxalactam kinetics during continuous ambulatory peritoneal dialysis after intraperitoneal administrationClinical pharmacology of moxalactam in patients with malignant disease.Moxalactam therapy for a wide spectrum of bacterial infections in adults.Therapy of lower respiratory tract infections with moxalactam.Clinical evaluation of moxalactam.Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy.Comparative in vitro study of SQ26,776.Comparative in vitro study of temocillin (BRL 17421), a new penicillin.Clinical and pharmacokinetic evaluation of parenteral moxalactam in infants and children.Penetration of moxalactam and cefazolin into atrial appendage after simultaneous intramuscular or intravenous administration.Differences in susceptibilities of species of the Bacteroides fragilis group to several beta-lactam antibiotics: indole production as an indicator of resistance.Effect of clavulanic acid on the activities of ten beta-lactam agents against members of the Bacteroides fragilis group.Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method.Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections.Susceptibility of anaerobic bacteria to nine antimicrobial agents and demonstration of decreased susceptibility of Clostridium perfringens to penicillin.Inconsistency of synergy between the beta-lactamase inhibitor CP-45,899 and beta-lactam antibiotics against multiply drug-resistant Enterobacteriaceae and pseudomonas species.Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.Activity of moxalactam and cefotaxime alone and in combination with ampicillin or penicillin against group B streptococci.Biliary excretion of moxalactam.Comparative in vitro activity of new beta-lactam antibiotics against anaerobic bacteria.In vitro activity of moxalactam and mecillinam, singly and in combination, against multi-drug-resistant Enterobacteriaceae and Pseudomonas species.Comparative in vitro activities of N-formimidoyl thienamycin and moxalactam against nonfermentative aerobic gram-negative rods.In vitro susceptibility of cephalothin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to Amikacin and selected new beta-lactam agents.Comparative in vitro activities of beta-lactam-tobramycin combinations against Pseudomonas aeruginosa and multidrug-resistant gram-negative enteric bacilliComparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.Comparative susceptibilities of clinical isolates of Serratia marcescens to newer cephalosporins, alone and in combination with various aminoglycosides.Single- and multiple-dose pharmacokinetics of moxalactam in normal subjectsAminoglycoside-resistant gram-negative bacilli in a community hospital: comparative in vitro activity of cefotaxime, moxalactam, cefoperazone, and piperacillin.Randomized comparative study of moxalactam and cefazolin in the treatment of acute urinary tract infections in adults.Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa.[N-formimidoyl-thienamycin: in vitro activity in bacteria with resistance to beta-lactam antibiotics or gentamicin].Comparative activity of N-formimidoyl thienamycin with third generation cephalosporins and ureido penicillins against multiple resistant Serratia marcescens.
P2860
Q30450692-E3CAE9C2-8364-4222-BF64-0793FD1D3C22Q30451388-C5E9026D-1839-4F06-BD23-D2148976689CQ33730322-52DA4288-72FD-4824-A02D-B12062038DC8Q34707883-7FEBCDE4-6B2B-406D-9E40-C765C2F31AC7Q35570414-7EF9261E-518E-4BEC-9D7B-88CE3A331790Q35570483-BA345D36-08FA-4EBD-9D14-17B38CFDEC49Q35646331-8B843DC2-C80B-406F-9ABD-754B9336C814Q35669389-1038B2EA-56F6-493E-86AF-B67BFDBA20C4Q35669539-33AFDFB6-1A50-41B4-AE80-4DC2177D2568Q35669739-86D987FC-CA6C-4EB5-983E-B29E31B8DFCCQ35670939-8054B8D1-CD72-4157-8FF6-F4C6864F788BQ35671449-F60FA959-C9BA-4FBA-9B0A-95E409F4109BQ35673771-91B9601B-113A-4004-ACE6-AD56CB292892Q35675199-04B7793E-07EC-4DCC-9D08-463D15CD9441Q35676060-562CDCF6-4680-475A-9717-02A38EAF20D3Q35714228-6B96AA48-AE9F-4E18-8A55-B301498AF514Q35718303-F4AC6C7E-C1E7-43DF-AE66-BB16AC0F593FQ35760318-61347989-55B1-46F5-8019-04D4204CA955Q35761083-658CDC47-2450-42E5-81F1-BA5D055C75EFQ35761938-648666A1-FFAB-405E-95B7-D4F57398E605Q39854364-129A4C97-0214-49A5-95AE-768B77A800F2Q39854642-81E3D7FD-BB95-4260-A100-F910AC899EFFQ39854724-1E0EB408-FCAD-4691-AD88-972FA328B772Q39855029-C7A99EBE-4BF1-423F-B786-7AC6D90BE86DQ39855579-497A96BD-A93E-4925-8A46-77BF5CCF6B61Q39856001-28FD1CFA-FA2B-46FD-8986-66F4C7808383Q39856404-DAFCF4C1-BEC2-4A6C-A20B-248CE57D603AQ39856904-7B0883FC-80B8-42C7-96C0-B365533F1938Q39857062-48F075FD-AA1C-4A5C-BA3F-24F147F9F184Q39857307-FE69B762-C0D8-434B-A0C3-2990B1176FC1Q40281490-6B998244-AD45-47E7-99BB-3C6DAE09077CQ40283012-8BC779F1-3160-4C9D-847C-8A21424135EDQ40283040-94C7502E-AEB0-4085-9F83-A065BCC630F0Q41850216-FD636B51-6ED1-4705-A992-25CB43AAB170Q42134415-11B06478-07E1-4FA0-A4C5-6AC56DA2CCE3Q42248639-69C4A0D6-05F6-4039-8F34-BEF11D060B89Q42928358-4FEFCBCB-E38F-40F2-BF6E-C52F1A9501C3Q44882404-3D83FCD3-8BE9-422D-9694-8C6FA3291B97Q54543524-DFA2DBD0-666C-4BA5-985D-7E7BF0C0574B
P2860
description
1979 nî lūn-bûn
@nan
1979年の論文
@ja
1979年論文
@yue
1979年論文
@zh-hant
1979年論文
@zh-hk
1979年論文
@zh-mo
1979年論文
@zh-tw
1979年论文
@wuu
1979年论文
@zh
1979年论文
@zh-cn
name
In vitro activity of LY127935.
@en
In vitro activity of LY127935.
@nl
type
label
In vitro activity of LY127935.
@en
In vitro activity of LY127935.
@nl
prefLabel
In vitro activity of LY127935.
@en
In vitro activity of LY127935.
@nl
P356
P1476
In vitro activity of LY127935.
@en
P2093
P2860
P304
P356
10.1128/AAC.16.4.503
P407
P577
1979-10-01T00:00:00Z